Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl filed a Form 4 on November 18, 2026, disclosing two open-market sales of common stock totaling 24,450 shares on November 16 and 17, 2026, along with a concurrent Employee Stock Purchase Plan acquisition.
Key Highlights
- First sale: Powl disposed of 9,196 shares on November 16, 2026 at $7.44 per share in a sell-to-cover transaction for taxes associated with the vesting of an RSU dated November 13, 2025.
- Second sale: Powl disposed of 15,254 shares on November 17, 2026 at a weighted average price of $7.45, with individual trade prices ranging from $7.24 to $7.74, pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026.
- RSU vesting: The shares sold on November 17 were acquired upon vesting of restricted stock units on November 13, 2026, according to the filing.
- ESPP acquisition: 896 shares were acquired on November 17, 2026 pursuant to the issuer's Employee Stock Purchase Plan.
- Remaining ownership: Following all reported transactions, Powl directly beneficially owned 113,265 shares of common stock, the filing states.
- 10b5-1 plan: The November 17 sales were effected under a Rule 10b5-1 trading plan the reporting person adopted on May 22, 2026.
Powl's November 2026 Share Dispositions and RSU Vesting at Kura Oncology
According to the Form 4 filed with the SEC on November 18, 2026, Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc. (NASDAQ:KURA), reported two separate dispositions of common stock over consecutive trading days. On November 16, 2026, Powl sold 9,196 shares at $7.44 per share. The filing identifies this transaction as a sell-to-cover for taxes associated with the vesting of a restricted stock unit granted on November 13, 2025.
On November 17, 2026, Powl sold an additional 15,254 shares at a weighted average price of $7.45. The filing notes that this sale was executed in multiple trades at prices ranging from $7.24 to $7.74, and that Powl undertakes to provide full details of individual trade prices and quantities upon request by the SEC staff, the issuer, or a security holder. These shares were acquired upon the vesting of restricted stock units on November 13, 2026, and the sales were effected pursuant to a Rule 10b5-1 trading plan that Powl adopted on May 22, 2026. Separately, 896 shares were acquired on November 17, 2026 through the issuer's Employee Stock Purchase Plan.
After all reported transactions, the filing shows Powl directly held 113,265 shares of Kura Oncology common stock. All transactions are reported as direct ownership. The Form 4 was signed by Teresa Bair, Attorney-in-fact for Brian Powl, and dated November 18, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Kura Oncology's Chief Commercial Officer Brian T. Powl disclosed the sale of 24,450 shares of common stock across two days in November 2026, one as a tax-related sell-to-cover and one under a 10b5-1 plan, along with an ESPP acquisition of 896 shares, leaving him with 113,265 shares directly held.



Please wait processing your request...